Cargando…
Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation
BACKGROUND: FTY720 (fingolimod, Gilenya™) is a daily oral therapy for multiple sclerosis that readily accesses the central nervous system (CNS). FTY720 is a structural analog to the sphingolipid sphingosine-1-phosphate (S1P) and is a cognate ligand for the S1P G-protein coupled receptors (S1PR). Stu...
Autores principales: | Wu, Celina, Leong, Soo Y, Moore, Craig S, Cui, Qiao Ling, Gris, Pavel, Bernier, Louis-Philippe, Johnson, Trina A, Séguéla, Philippe, Kennedy, Timothy E, Bar-Or, Amit, Antel, Jack P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621211/ https://www.ncbi.nlm.nih.gov/pubmed/23509960 http://dx.doi.org/10.1186/1742-2094-10-41 |
Ejemplares similares
-
FTY720 attenuates excitotoxicity and neuroinflammation
por: Cipriani, Raffaela, et al.
Publicado: (2015) -
FTY720-derivatives do not induce FTY720-like lymphopenia
por: Segura-Ulate, Ismael, et al.
Publicado: (2017) -
New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth
por: Alshaker, Heba, et al.
Publicado: (2017) -
The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
por: Patmanathan, Sathya Narayanan, et al.
Publicado: (2015) -
The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016)